🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/06/2017 | 124,00 | 127,89 | 123,54 | 127,16 | +2,88% | 3,51% | 3.356.300 |
| 31/05/2017 | 120,95 | 123,78 | 120,61 | 123,60 | +2,67% | 2,62% | 2.813.600 |
| 30/05/2017 | 119,52 | 120,99 | 119,19 | 120,39 | +0,39% | 1,51% | 1.634.800 |
| 26/05/2017 | 118,10 | 120,82 | 118,05 | 119,92 | +1,11% | 2,35% | 1.477.800 |
| 25/05/2017 | 118,00 | 119,42 | 117,38 | 118,60 | +0,68% | 1,73% | 1.393.200 |
| 24/05/2017 | 116,86 | 118,44 | 115,10 | 117,80 | +1,04% | 2,86% | 1.818.300 |
| 23/05/2017 | 118,94 | 119,27 | 115,87 | 116,59 | -1,98% | 2,86% | 1.860.000 |
| 22/05/2017 | 118,57 | 119,27 | 117,51 | 118,94 | +0,78% | 1,48% | 1.062.000 |
| 19/05/2017 | 117,77 | 118,82 | 117,10 | 118,02 | +0,08% | 1,46% | 1.564.700 |
| 18/05/2017 | 115,55 | 118,61 | 115,42 | 117,93 | +3,10% | 2,76% | 2.154.800 |
| 17/05/2017 | 117,44 | 117,88 | 114,20 | 114,38 | -3,14% | 3,13% | 1.717.900 |
| 16/05/2017 | 117,36 | 118,13 | 115,13 | 118,09 | +1,60% | 2,56% | 1.320.400 |
| 15/05/2017 | 114,64 | 116,35 | 113,80 | 116,23 | +1,42% | 2,22% | 1.100.500 |
| 12/05/2017 | 115,12 | 116,23 | 113,84 | 114,60 | -0,66% | 2,08% | 986.000 |
| 11/05/2017 | 115,41 | 115,54 | 113,84 | 115,36 | +0,01% | 1,47% | 1.395.100 |
| 10/05/2017 | 116,55 | 116,55 | 114,22 | 115,35 | -1,10% | 2,00% | 1.414.000 |
| 09/05/2017 | 115,50 | 117,00 | 114,38 | 116,63 | +1,36% | 2,27% | 1.185.200 |
| 08/05/2017 | 114,56 | 115,65 | 113,81 | 115,06 | +0,19% | 1,61% | 1.544.400 |
| 05/05/2017 | 116,54 | 116,70 | 113,66 | 114,84 | -1,33% | 2,61% | 2.545.100 |
| 04/05/2017 | 119,59 | 119,95 | 115,91 | 116,39 | -2,23% | 3,38% | 1.672.700 |
| 03/05/2017 | 118,52 | 119,36 | 117,88 | 119,05 | +0,49% | 1,25% | 1.333.300 |
| 02/05/2017 | 120,82 | 121,96 | 116,40 | 118,47 | -1,78% | 4,60% | 2.465.400 |
| 01/05/2017 | 118,98 | 120,73 | 117,99 | 120,62 | +1,96% | 2,30% | 2.108.800 |
| 28/04/2017 | 119,50 | 120,50 | 115,45 | 118,30 | +0,75% | 4,23% | 3.387.200 |
| 27/04/2017 | 116,00 | 118,26 | 116,00 | 117,42 | +0,93% | 1,95% | 1.424.400 |
| 26/04/2017 | 118,08 | 118,08 | 116,07 | 116,34 | -0,79% | 1,70% | 1.759.100 |
| 25/04/2017 | 117,79 | 118,41 | 116,92 | 117,27 | -0,33% | 1,26% | 1.243.000 |
| 24/04/2017 | 117,66 | 118,79 | 117,31 | 117,66 | +0,82% | 1,26% | 1.503.000 |
| 21/04/2017 | 117,17 | 117,69 | 115,92 | 116,70 | -0,48% | 1,51% | 2.803.900 |
| 20/04/2017 | 115,20 | 117,99 | 114,13 | 117,26 | +2,29% | 3,35% | 1.495.500 |